Miguel Bergna

1.9k total citations
21 papers, 494 citations indexed

About

Miguel Bergna is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Miguel Bergna has authored 21 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 3 papers in Surgery. Recurrent topics in Miguel Bergna's work include Asthma and respiratory diseases (11 papers), Respiratory and Cough-Related Research (10 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Miguel Bergna is often cited by papers focused on Asthma and respiratory diseases (11 papers), Respiratory and Cough-Related Research (10 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Miguel Bergna collaborates with scholars based in Argentina, United States and Spain. Miguel Bergna's co-authors include Gustavo Zabert, Santiago Perez‐Lloret, Christopher L. Drake, Daniel P. Cardinali, Daniel Pérez-Chada, Alejandro J. Videla, Bradley E. Chipps, Kenneth R. Chapman, Dmitry Galkin and Xavier Muñoz and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Journal of Allergy and Clinical Immunology and SLEEP.

In The Last Decade

Miguel Bergna

18 papers receiving 474 citations

Peers

Countries citing papers authored by Miguel Bergna

Since Specialization

Citations

This map shows the geographic impact of Miguel Bergna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Bergna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Bergna more than expected).

Fields of papers citing papers by Miguel Bergna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Bergna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Bergna. The network helps show where Miguel Bergna may publish in the future.

Co-authorship network of co-authors of Miguel Bergna

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Bergna. A scholar is included among the top collaborators of Miguel Bergna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Bergna. Miguel Bergna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Late Breaking Abstract - ELEVATE IPF phase 2b open-label extension demonstrates durable efficacy of deupirfenidone 2025 ·Αrgyris Τzouvelekis, Mark J. Hamblin, Won Il Choi, Amy Hajari Case, Ioannis Tomos, (unknown), Miguel Bergna, David A. Golod, Eric Elenko, Yanqiong Zhang, Camilla S. Graham, Jin Woo Song, (unknown), Toby M. Maher	0
2	Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial 2025 ·American Journal of Respiratory and Critical Care Medicine ·Toby M. Maher, Miguel Bergna, Amy Hajari Case, Won-Il Choi, Mark J. Hamblin, Tejaswini Kulkarni, (unknown), Ioannis Tomos, Αrgyris Τzouvelekis, David A. Golod, Eric Elenko, (unknown), Camilla S. Graham, Jin Woo Song, (unknown)	1
3	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics 2021 ·Respiratory Research ·Mark C. Liu, Bradley E. Chipps, Xavier Muñoz, Gilles Devouassoux, Miguel Bergna, Steven G. Smith, Robert G. Price, Dmitry Galkin, (unknown), (unknown), Frank C. Albers, Kenneth R. Chapman	22
4	Incorporating new evidence on inhaled medications in COPD. The latin American chest association (ALAT) 2019 2020 ·Archivos de Bronconeumología ·María Montes de, María Victorina López Varela, (unknown), Eduardo Schiavi, Alejandro Casas, (unknown), (unknown), Alejandra Ramírez‐Venegas, Gabriel García, Aquiles Assunção Camelier, Miguel Bergna, Mark E. Cohen, (unknown), Santiago Guzmán, (unknown), (unknown), (unknown)	10
5	Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration 2019 ·Journal of Allergy and Clinical Immunology ·Frank C. Albers, Mark C. Liu, Bradley E. Chipps, Kenneth R. Chapman, Xavier Muñoz, Miguel Bergna, Gilles Devouassoux, (unknown), Robert G. Price, Dmitry Galkin	4
6	Incorporando nuevas evidencias sobre medicamentos inhalados en la EPOC. Asociación Latinoamericana de Tórax (ALAT) 2019 2019 ·Archivos de Bronconeumología ·María Montes de, María Victorina López Varela, (unknown), Eduardo Schiavi, Alejandro Casas, (unknown), (unknown), Alejandra Ramírez‐Venegas, Gabriel García, Aquiles Assunção Camelier, Miguel Bergna, Mark E. Cohen, (unknown), Santiago Guzmán, (unknown), (unknown), (unknown)	10
7	The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma 2019 ·Allergy ·Kenneth R. Chapman, Frank C. Albers, Bradley E. Chipps, Xavier Muñoz, Gilles Devouassoux, Miguel Bergna, Dmitry Galkin, (unknown), (unknown), Robert G. Price, Mark C. Liu	109
8	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence 2018 ·European Respiratory Review ·Luca Richeldi, Francesco Varone, Miguel Bergna, João A. de Andrade, Jeremy Falk, Robert W. Hallowell, S. Jouneau, Yasuhiro Kondoh, Lee E. Morrow, Winfried Randerath, Mary E. Strek, (unknown)	67
9	Patient perception of Breezhaler^® and Ellipta^® device feedback mechanisms in COPD: The ADVANTAGE Study 2018 ·Current Medical Research and Opinion ·Pablo Altman, Miguel Bergna, (unknown), Tadhg Guerin, (unknown), (unknown)	4
10	Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes 2018 ·Journal of Allergy and Clinical Immunology ·Dmitry Galkin, Mark C. Liu, Bradley E. Chipps, Kenneth R. Chapman, Xavier Muñoz, Miguel Bergna, (unknown), (unknown), (unknown), Frank C. Albers	12
11	Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Asthma Control, Quality of Life and Lung Function Outcomes 2018 ·Journal of Allergy and Clinical Immunology ·Frank C. Albers, Mark C. Liu, Bradley E. Chipps, Kenneth R. Chapman, Xavier Muñoz, Miguel Bergna, (unknown), (unknown), (unknown), Dmitry Galkin	6
12	Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT-2014: Preguntas y respuestas 2015 ·Archivos de Bronconeumología ·María Montes de, María Victorina López Varela, (unknown), Eduardo Schiavi, (unknown), José Roberto Jardim, Alejandro Casas, (unknown), (unknown), Alejandra Ramírez‐Venegas, Gabriel García, Roberto Stirbulov, Aquiles Assunção Camelier, Miguel Bergna, Mark E. Cohen, Santiago Guzmán, (unknown)	38
13	Development of a simple binary response questionnaire to identify airflow obstruction in a smoking population in Argentina 2015 ·European Respiratory Review ·Miguel Bergna, (unknown), (unknown), (unknown), (unknown), (unknown), Luís J. Nannini, (unknown), (unknown), Gustavo Zabert, Marc Miravitlles	6
14	ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines: Questions and Answers 2015 ·Archivos de Bronconeumología ·María Montes de, María Victorina López Varela, (unknown), Eduardo Schiavi, (unknown), José Roberto Jardim, Alejandro Casas, (unknown), Carlos A. Torres‐Duque, Alejandra Ramírez‐Venegas, Gabriel García, Roberto Stirbulov, Aquiles Assunção Camelier, Miguel Bergna, Mark E. Cohen, Santiago Guzmán, (unknown)	30
15	Obstrucción crónica de la vía aérea en un paciente de 18 años 2014 ·Redalyc (Universidad Autónoma del Estado de México) ·(unknown), (unknown), Miguel Bergna, (unknown), (unknown), Vanina Martín, (unknown), (unknown), Sílvia Quadrelli	0
16	Increased exhaled breath temperature in subjects with uncontrolled asthma 2013 ·The International Journal of Tuberculosis and Lung Disease ·(unknown), Miguel Bergna, (unknown), Aina M. Yáñez, Joan B. Soriano	19
17	Exhaled breath temperature in COPD patients 2012 ·(unknown), Miguel Bergna, (unknown)	1
18	Acute asthma in Buenos Aires 2012 ·(unknown), Miguel Bergna, Luís J. Nannini, Hugo Neffen, Gustavo J. Rodrigo, (unknown)	2
19	Exhaled breath temperature in adult cystic fibrosis 2011 ·(unknown), (unknown), (unknown), (unknown), (unknown), Miguel Bergna	5
20	Sleep Disordered Breathing And Daytime Sleepiness Are Associated With Poor Academic Performance In Teenagers. A Study Using The Pediatric Daytime Sleepiness Scale (PDSS) 2007 ·SLEEP ·Daniel Pérez-Chada, Santiago Perez‐Lloret, Alejandro J. Videla, Daniel P. Cardinali, Miguel Bergna, (unknown), (unknown), Gustavo Zabert, Christopher L. Drake	148

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact